Agile Therapeutics, Inc. President and Chief Executive Officer Al Altomari is an Ernst & Young LLP Entrepreneur of the Year(R) 2012 Finalist in New Jersey

PRINCETON, NJ--(Marketwire - May 15, 2012) -

Agile Therapeutics today announced that President and Chief Executive Officer Al Altomari was named a finalist in the Ernst & Young Entrepreneur Of The Year® 2012 program in the New Jersey region. The award recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities. Awards will be presented at a special gala on June 27, 2012 at the Hyatt New Brunswick.

Now in its 26th year, the Entrepreneur Of The Year Program has expanded to recognize business leaders in more than 140 cities in more than 50 countries throughout the world.

Regional award winners are eligible for consideration for the Ernst & Young National Entrepreneur Of The Year Program. Award winners in several national categories, as well as the Ernst & Young National Entrepreneur Of The Year Overall Award winner, will be announced at the annual awards gala in Palm Springs, California, on November 17, 2012. The awards are the culminating event of the Ernst & Young Strategic Growth Forum, the nation’s most prestigious gathering of high-growth, market-leading companies.

Sponsors
Founded and produced by Ernst & Young LLP, the Entrepreneur Of The Year Awards are nationally sponsored in the United States by SAP America and the Ewing Marion Kauffman Foundation.

In New Jersey, sponsors include PNC, Merrill Corporation, Morgan Lewis & Bockius, DLA Piper, Scherzer International, Empire Valuation Consultants, WithumSmith +Brown, Murray Devine, Gibbons, P.C., New Jersey Technology Council, SolomonEdwards Group, and New Jersey Business Journal.

About Agile Therapeutics
Agile Therapeutics is a pharmaceutical development company specializing in Women’s Healthcare products, with an initial focus on providing women with more options and more convenient methods of hormonal contraception. The company’s lead product, AG200-15, is a once-weekly contraceptive patch that recently completed Phase III clinical trials. In addition, Agile is also developing a low dose, progestin-only contraceptive patch, AG890 (formerly AG900). Both AG200-15 and AG890 incorporate proprietary transdermal delivery technology, Skinfusion®, developed by Agile, consisting of an active and peripheral adhesive system that allows stable drug delivery and dependable adhesion over seven days. For more information, please visit http://www.agiletherapeutics.com.

About Ernst & Young Entrepreneur Of The Year®
Ernst & Young Entrepreneur Of The Year is the world’s most prestigious business award for entrepreneurs. The unique award makes a difference through the way it encourages entrepreneurial activity among those with potential, and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 140 cities in more than 50 countries.

About Ernst & Young
Ernst & Young is a global leader in assurance, tax, transaction and advisory services. Worldwide, our 152,000 people are united by our shared values and an unwavering commitment to quality. We make a difference by helping our people, our clients and our wider communities achieve their potential.

Ernst & Young refers to the global organization of member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit www.ey.com.

This news release has been issued by Ernst & Young LLP, a US client-serving member firm of Ernst & Young Global Limited.